Young Kwang Chae, MD, MPH, MBA
Dr. Young Kwang Chae is a medical oncologist and researcher with Northwestern Medicine in Chicago, Illinois, and an Associate Professor of Medicine in the Hematology Oncology Division of the Feinberg School of Medicine. He specializes in treating patients with malignant mesothelioma, lung cancer, breast cancer, and other cancers with a special focus on the use of novel treatments, precision medicine, and targeted therapies.[1]
Dr. Chae is actively involved in oncology research, a passion that was ignited by his dissatisfaction with suboptimal cancer treatment. He sees a significant need for a more personalized cancer treatment and believes that rapid progress in cancer genomics and immunology will soon be translated into improved patient outcomes. He enjoys collaborating with world leaders in medicine to bring the best science to patients through innovative clinical trials and biomarker-based treatments.[2]
Education and Career
Dr. Chae earned his medical degree at Seoul National University College of Medicine, then completed an internship and residency in Internal Medicine at Albert Einstein Healthcare Network. He completed a fellowship in Hematology and Medical Oncology at the University of Texas Health Science Center at Houston/M.D. Anderson Cancer Center.[1]
Research
Dr. Chae’s research is broadly focused on personalized cancer therapy. His interests include:[1]
- Precision medicine
- Early-phase clinical trials
- First-in-human studies
- Novel combination cancer therapy
- Targeted therapy
- Immunotherapy
- Biomarker study
- Novel drug development
- Novel drug delivery system
- Adaptive clinical trials design
- Cell signaling pathway
- Immune checkpoint pathway
Recent Publications[1]
- A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia. Patel,SP; Othus,M; Chae,YK; Dennis,MJ; Gordon,S; Mutch,D; Samlowski,W; Robinson,WRR; Sharon,E; Ryan,C; Lopez,G; Plets,M; Blanke,C; Kurzrock,R. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 Jan; 1557-3265. PMID: 37882676
- Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175. Gentzler,RD; Mohindra,NA; Jalal,SI; Reckamp,KL; Hall,RD; Hanna,NH; Chae,YK; Koczywas,M; Helenowski,IB; Patel,JD. The oncologist 2024 Jan; 1549-490X. PMID: 37390616
- Survival Outcomes After Double-Lung Transplantation for Refractory Lung-Limited Cancers and Incidence of Post-Transplant Lung Cancer. Lee,J; Aguilera Chuchuca,MJ; Yu,J; Chung,LI; Bharat,A; Chae,YK. Annals of transplantation. 2023 ; PMID: 38050347
- Papillary thyroid cancer immune phenotypes via tumor-infiltrating lymphocyte spatial analysis. Nam,M; Yang,W; Kim,HS; Park,J; Park,G; Kim,S; Song,S; Ock,CY; Wang,VG; Chuang,JH; Chae,YK. Endocrine-related cancer 2023 Sep; 1479-6821. PMID: 37279258
- Current and future role of double-lung transplantation for bilateral lung cancer. Lee,J; Schellenberg,SJ; Chung,LI; Bharat,A; Chae,YK. Transplantation reviews (Orlando, Fla.) 2023 Jul;. PMID: 37356213
